| Detected | Trial | Change |
|---|---|---|
| 2026-07-30 | NCT05645107 A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT)… |
date change Primary completion pushed: 2026-05 -> 2029-08 |
| 2026-07-30 | NCT05645107 A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT)… |
date change Completion pushed: 2026-06 -> 2029-08 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07540221 | A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in… | CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) | Recruiting |
| NCT05645107 | A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT)… | Hypogammaglobulinemia | Recruiting |
| NCT07555483 | A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of… | Alpha 1 Antitrypsin Deficiency | Recruiting |
| NCT01983241 | Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP)… | Pulmonary Emphysema in Alpha-1 PI Deficiency | Active, Not Recruiting |
| NCT02796937 | Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin… | Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency | Enrolling by Invitation |